原创力文档2024肺癌ASCO最新进展之Managing Expectations WithAntibody-Drug Conjugates in Non-Small Cell Lung Cancer.pdf
- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
ManagingExpectationsWithAntibody–DrugConjugatesinNon–SmallCellLungCancer
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
KeyTakeAways
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
WhatexpectationsofADC’s?–ASCO2022
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
AntibodyDrugConjugatesdiscussedtoday
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
WhyTargetTROP2?
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
Phase3TrialsofAnti-TROP2ADCsinPretreatedPatients
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
SimilarOutcomes
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
Similaroutcomes
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
Somesubtledifferences
Contentofthispresentationisthepropertyoftheauthor,licensedbyASCO.Permissionrequiredforreuse.
Areweadministeringcytotoxicsinatoocomplicatedway?
Contentofthispresentat
您可能关注的文档
- 2024ASCO肺癌之ASCO2024-Ⅲ期LAURA主要研究结果.pdf
- 中国肿瘤整合诊治指南（CACA) 乳腺癌试题库_V1.0_2023（20230424）.pdf
- 中国肿瘤整合诊治指南（CACA) 肺癌试题库_V1.0_2023（20230428）.pdf
- 2024肺癌ASCO最新进展之Lorlatinib vs Crizotinib in Treatment-NaivePatients With Advanced ALK+ Non-SmallCell Lung Cancer 5-Year Progression-FreeSurvival and Safety From the CRoWN Study.pdf
- 2024肺癌ASCO最新进展之Milestones Early Detection to Nodal Status and Every thing in Between.pdf
- 2024肺癌ASCO最新进展之Molecular residual disease analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage lB-lllA non-small cell lung cancer.pdf
- 2024肺癌ASCO最新进展之Neoadjuvant nivolumab plus chemotherapy vschemotherapy in patients with resectable NSCLC4-year update from CheckMate 816.pdf
- 2024肺癌ASCO最新进展之Niraparib and Dostarlimab efficacy in patients with platinum.sensitive relapsed mesothelioma MlST5, a phase lla clinicaltrial.pdf
- 2024肺癌ASCO最新进展之NRG-LU002Randomized Phase lllll Trial Of MaintenanceSystemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer.pdf
- 2024肺癌ASCO最新进展之Outcomes with Perioperative Durvalumab in Patientswith Resectable NSCLc and Baseline N2 Lymph NodeInvolvement(N2 R-NSCLC).pdf
- 2024肺癌ASCO最新进展之Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-f.pdf
- 2024肺癌ASCO最新进展之Sacituzumab Tirumotecan (sac-TMT; Also Known asSKB264MK-2870)in Combination With KL-A167 (Anti-PD-L1)as First-Line Treatment for Patients With Advanced NSCLCFrom the Phase ll OptiTRoP-Lung01 Study.pdf
- 2024肺癌ASCO最新进展之Safety and efficacy of osimertinib plus consolidativestereotactic ablative radiation(SABR) inadvanced EGFR mutant non-small cell lungcancer(NSCLC)results from a multi-center Phase ltrial.pdf
- 2024肺癌ASCO最新进展之slides-Overall_survival_of_adebrelimab_plus_chemotherapy_..pdf
最近下载
- 规范《DLT519-2014-发电厂水处理用离子交换树脂验收标准》.pdf VIP
- 2022-2023学年河南省驻马店市确山县小升初英语试卷.doc VIP
- 智慧体育进校园运动设备采购项目技术方案.docx VIP
- 2024年新高考数学一轮复习题型归类与强化测试（新高考专用）专题15 导数的概念及运算 Word版含解析.docx VIP
- 喷砂机的日常维护与保养规程.docx VIP
- 数字低空系列—通感一体赋能数字低空网络白皮书-98页.pdf
- 米家forestlife除湿机FLE20-5252使用说明书.pdf
- 病原微生物实验室生物安全风险管理指南RB∕T 040-2020.doc
- 卫生标准操作程序（SSOP）.ppt VIP
- 2023年河南省驻马店市确山县小升初数学试卷.doc VIP
- 科研立项/文案设计/翻译润色/PPT制作 + 关注
-
实名认证服务提供商
提供肿瘤指南资料、指导自然科研立项、各类文案设计、文章翻译润色、PPT制作等相关服务，可咨询QQ：731689706
文档评论（0）